View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 25, 2011

European Medicines Agency Recommends Liver Cancer Drug

German drug developer 4SC has announced that resminostat, a drug for the treatment of hepatocellular carcinoma – the most common form of liver cancer – has been recommended for approval by the European Medicines Agency. The recommendation has been forwarded to the EU commission for the

By cms admin

German drug developer 4SC has announced that resminostat, a drug for the treatment of hepatocellular carcinoma – the most common form of liver cancer – has been recommended for approval by the European Medicines Agency .

The recommendation has been forwarded to the EU commission for the final approval and publication in the community register.

The news follows the recent orphan drug designation granted by the US Food and Drug Administration for the same programme.

4SC CEO Ulrich Dauer said that both designations “emphasise the importance of developing novel therapies in this indication in order to provide effective treatment options to patients suffering from this life-threatening disease”.

The European Medicines Agency ‘s orphan medicinal product designation includes a ten-year period of market exclusivity from the date of approval for drugs and biologics that address rare diseases that affect no more than five in 10,000 people in the EU.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology